Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of a drug called BMS-986368 in adults with Multiple Sclerosis Spasticity. This Phase 2 trial compares three different doses of the drug administered orally against a placebo. The study focuses on participants aged 18 to 70 who have a confirmed diagnosis of multiple sclerosis with spasticity lasting at least 6 months. Participants are randomly assigned to one of four groups three groups receive different doses of BMS-986368, and one group receives a placebo. The drug is given on specified days, though exact dosing schedules are not detailed in the summary. The study is double-blind, meaning neither participants nor most study staff know who receives the active drug or placebo. This treatment phase is planned to last at least 6 weeks, during which various assessments will take place. During the study, participants undergo evaluations including the Modified Ashworth Scale for spasticity, Numeric Rating Scale for spasticity severity, Timed 25-Foot Walk, and other clinical assessments. Blood samples will be collected to measure plasma levels of BMS-986368. Safety is closely monitored up to 16 weeks, including adverse events and withdrawal symptoms. The main outcome measure tracks changes in spasticity score at 6 weeks. Participants progress will be assessed through scheduled visits, and the total participation duration may extend beyond the treatment period for safety follow-up.
Actively Recruiting
This research aims to evaluate the long-term safety and tolerability of inhaled antifibrotic medications, specifically AP01, in participants who have previously completed Avalyn Pharma sponsored studies involving this treatment. The study focuses on individuals with progressive pulmonary fibrosis or idiopathic pulmonary fibrosis IPF, excluding IPF subjects from the US and Canada. The goal is to continue assessing the effects of AP01 over an extended period. Participants will receive 100 mg of inhaled pirfenidone solution AP01 twice daily using the eFlow Nebulizer System. The study includes a ScreeningBaseline Visit, an open-label Treatment Period where all participants receive AP01, and a Follow-upEnd of Study phone call approximately two weeks after the last dose. The dosing during the treatment period will be monitored with a paper diary and by collecting any unused medication. Throughout the study, participants will be assessed for long-term safety and tolerability outcomes, including changes in lung function measured by forced vital capacity FVC, disease stabilization, and quality of life. The trial is expected to last an average of six years, with evaluations continuing until the studys end. Participants will have regular monitoring and follow-up to track their progress and adherence to the treatment.
Actively Recruiting
Researchers are conducting a phase 3, randomized, multicenter, double-masked study to evaluate the effectiveness and safety of intranasal cenegermin compared with a vehicle control in adults with Non-Arteritic Anterior Ischemic Optic Neuropathy NAION. This condition affects the optic nerve and can lead to vision loss. The study aims to determine whether cenegermin can improve visual outcomes for participants. Participants will be randomly assigned to one of two groups one receiving cenegermin spray in each nostril and the other receiving a vehicle spray as a comparator. Treatments are administered intranasally. The study compares these two interventions over a treatment period lasting up to 24 weeks, during which visual acuity and other eye health measures are assessed. Throughout the study, participants will undergo regular assessments including measurements of best corrected visual acuity BCVA using the ETDRS chart, visual field sensitivity tests, and optical coherence tomography OCT to evaluate retinal layers. Safety is monitored by tracking ocular and non-ocular adverse events. The primary outcome is the achievement of a 15-letter or greater improvement in BCVA from baseline to week 24. The total participation duration extends through the 24-week treatment and evaluation period.